Navigation Links
OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Second Quarter 2011 and Provides Update on Development Activities
Date:8/4/2011

andidate, custirsen. Custirsen is currently in Phase 3 clinical development as a treatment in men with metastatic castrate-resistant prostate cancer. The companies plan to begin Phase 3 development of custirsen in first-line treatment of advanced, unrespectable non-small cell lung cancer. OGX-427 is in Phase 2 clinical development; CSP-9222 and OGX-225 are currently in pre-clinical development.

OncoGenex' Forward Looking StatementsThis press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning our anticipated product development activities, such as expected clinical trial initiation and completion dates, patient enrollment targets, proposed amendments to our ongoing clinical trial design and the timing and possibility for approval by the FDA thereof, the timing and costs of our product development activities and the potential benefits of our product candidates. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. These statements are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements. Such forward-looking statements are subject to risks and uncertainties, including, among others, the risk of delays in our expected clinical trials and the uncertainties regarding patient enrollment rates, the risk that the FDA does not approve our proposed amendment to the Saturn trial design in a timely fashion or at all, the risk that our product candidates do not obtain the requisite regulatory approvals to commercialize, the risk that new developments in the rapidly evolving prostate cancer therapy landscape require additional changes in our clinical trial design or lim
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. OncoGenex Announces Data Highlighting OGX-427 at American Association of Cancer Research (AACR) 102nd Annual Meeting 2011
2. OncoGenex Pharmaceuticals to Participate in Panel Discussion on Novel Cancer Treatments at RBC Capital Markets Healthcare Conference
3. Isis Pharmaceuticals to Receive $10 Million From OncoGenex License of OGX-011 to Teva
4. OncoGenex Expands Clinical Development of OGX-427 with a Phase 1 Clinical Trial in Bladder Cancer
5. Keryx Biopharmaceuticals, Inc. to Host Conference Call on Second Quarter 2011 Financial Results
6. Pacira Pharmaceuticals, Inc. Announces Data Presentations at the 38th Annual Meeting & Exposition of the Controlled Release Society
7. Pacira Pharmaceuticals, Inc. Announces Timing for Second Quarter 2011 Financial Results Webcast and Conference Call
8. Visionary Pharmaceuticals, Inc., Announces Initial Seed Round Investments and the Launch of TH17 Autoimmune Disease Research Activities
9. Janssen Pharmaceuticals, Inc. Announces Definitive Agreement to Divest Ortho Dermatologics Division
10. Gamma Pharmaceuticals, Inc. Holds Special Shareholders Meeting
11. Sigma-Tau Pharmaceuticals, Inc. Announces Addition of VP of Finance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... , Sept. 23, 2014 ... of the "Physician Office Laboratory Markets, 3rd ... This report, Physician Office Laboratory Markets is ... the IVD industry. Physician office laboratories are diverse ... simply perform reimbursable, in-office pregnancy and glucose tests. ...
(Date:9/23/2014)... The Pennsylvania State Police will accept unwanted, expired ... of National Prescription Drug Take-Back Day. The service is ... Day is a national initiative, conducted in partnership with ... the public to dispose of expired, unused or unwanted ... From 10 a.m. to 2 p.m., unwanted ...
(Date:9/23/2014)... , Sept. 23, 2014 Research and ... "Biopharmaceutical and Vaccine Production Markets" report to their ... new therapies and vaccines - including products to treat ... still huge challenges during the final stages of clinical ... and how to risk production capital to upscale while ...
Breaking Medicine Technology:Physician Office Laboratory Markets, 3rd Edition 2Physician Office Laboratory Markets, 3rd Edition 3Biopharmaceutical and Vaccine Production Markets 2Biopharmaceutical and Vaccine Production Markets 3
... Inc. (OTC BB: NSPR) ("Inspire" or the "Company"), ... and commercialization of its proprietary stent platform technology, ... summary of  three years collective data will be ... Transcatheter Cardiovascular Therapeutics (TCT) conference. The conference is ...
... Express Scripts, Inc., one of the largest ... Rexam as its 2011 Supplier of the Year. ... This award recognizes suppliers who have a ... continuous improvement in supplier relationship management, quality, service, ...
Cached Medicine Technology:InspireMD to Sponsor Satellite Symposium Breakfast Meeting Chaired by Dr. Gregg W. Stone November 9th at TCT 2011 2InspireMD to Sponsor Satellite Symposium Breakfast Meeting Chaired by Dr. Gregg W. Stone November 9th at TCT 2011 3InspireMD to Sponsor Satellite Symposium Breakfast Meeting Chaired by Dr. Gregg W. Stone November 9th at TCT 2011 4Rexam Chosen as Express Scripts' Supplier of the Year 2
(Date:9/23/2014)... 2014 The inaugural single day event ... Hotel New Otani Tokyo Gardens in Tokyo. Clinical data scientists ... and validation. , The second single day event in ... offices in Shanghai. The clinical data scientists attending this event ... figures and listings, which display data collected in clinical studies ...
(Date:9/23/2014)... "The primary purpose of the CALL LIGHT ... from Sacramento, Ca.. "Call lights are often found on the ... the IV pole out of the patient's reach. In order ... whenever they need it, I created this caddy." , She ... call device within easy reach. The accessory ensures that the ...
(Date:9/23/2014)... Downingtown, PA (PRWEB) September 24, 2014 ... traumatic stress disorder (PTSD) – and how it can ... 31, was deployed in Iraq in 2006. His platoon ... home in 2008, he was diagnosed with combat-related PTSD ... withdrawn, I was angry, and I had distanced myself ...
(Date:9/23/2014)... Karen Pallarito HealthDay Reporter ... if doctors and hospitals got paid for providing better ... better data for making informed health choices. A ... is headed. The report, from the IMS Institute for ... -- recent events expected to alter the delivery of health ...
(Date:9/23/2014)... 2014 What information do patients ... Quality Forum (NQF) released a report ( http://bit.ly/1DwekE9 ... an infographic ( http://bit.ly/1tX3lzA ) resulting from an ... how patients define affordability, and what information and ... best possible healthcare at the lowest possible cost. ...
Breaking Medicine News(10 mins):Health News:PhUSE Further Expands its Global Community Into the Asian Region 2Health News:Virtual Reality software to help treat PTSD 2Health News:Virtual Reality software to help treat PTSD 3Health News:Report Identifies Game Changers for U.S. Health Care 2Health News:Report Identifies Game Changers for U.S. Health Care 3Health News:Finding Affordable Care: Asking the Right Question is Key 2
... , , , ROCHESTER, Minn., Sept. ... is the focus of a Perspectives article in ... 23, 2009, and in the print issue on Oct. 1, 2009. , ... , "We must hold physicians and other providers accountable for ...
... from the dried venom secreted by the skin glands of ... those normally administered, and may slow disease progression in some ... D. Anderson Cancer Center. The results from ... M. D. Anderson and Fudan University Cancer Hospital in Shanghai, ...
... The Weill Cornell Institute of Geriatric Psychiatry at ... the largest grant in its 20-year history. One ... million, five-year "Center Grant" from the National Institute ... investigators to advance their pioneering work in understanding ...
... registered in the past 30 years, cardiovascular disease (CVD) remains the ... In the EU, experts reveal that striking disparities still exist ... with regard to national prevention policies. In view of this, there ... tackle heart disease and stroke. The message coincides with ...
... ... ... -- Whether in a quest for beauty or out of necessity, millions of Americans will ... technologies, and research will be presented at Plastic Surgery 2009, the annual scientific meeting of ...
... flu not effective , THURSDAY, Sept. 24 (HealthDay News) ... give the wrong dose of Tamiflu to their children ... dosing instructions don,t always coincide with the measurement markings ... , The warning letter, penned by scientists from Northwestern ...
Cached Medicine News:Health News:Mayo Clinic Offers Perspective on Health Care Reform in New England Journal of Medicine 2Health News:M. D. Anderson examines use of toad venom in cancer treatment 2Health News:M. D. Anderson examines use of toad venom in cancer treatment 3Health News:Weill Cornell Institute for Geriatric Psychiatry awarded $10 million grant 2Health News:Weill Cornell Institute for Geriatric Psychiatry awarded $10 million grant 3Health News:Weill Cornell Institute for Geriatric Psychiatry awarded $10 million grant 4Health News:World Heart Day resonates with recent experts' findings on CVD and EU institutions' determination to promote heart health 2Health News:World Heart Day resonates with recent experts' findings on CVD and EU institutions' determination to promote heart health 3Health News:American Society Of Plastic Surgeons Hosts 78th Annual Meeting 2Health News:American Society Of Plastic Surgeons Hosts 78th Annual Meeting 3Health News:American Society Of Plastic Surgeons Hosts 78th Annual Meeting 4Health News:Letter Warns About Tricky Dosing With Liquid Tamiflu for Kids 2Health News:Letter Warns About Tricky Dosing With Liquid Tamiflu for Kids 3
... Bio-Rad isotopic anemia ... and minimal ,pipetting steps ... information about the processes ... and the benefit to ...
... Bio-Rad isotopic anemia assays ... minimal ,pipetting steps for ... about the processes ,involved ... the benefit to your ...
... The ImmunoDOT Autoimmunity Screening Panel ... test for screening and detection,of autoantibodies ... DNA, SS-A/SS-B, RNP/Sm) in serum, and ... diagnosis of systemic lupus erythematosus (SLE), ...
The MESACUP ANA Test Kit is a semi-quantitative enzyme-linked immunosorbent assay,(ELISA) for the detection of specific anti-nuclear antibodies in human serum as an aid in,the determination of autoim...
Medicine Products: